• AtheroNova Inc., of Irvine, Calif., completed its pre-investigational new drug application meeting with the FDA for AHRO-001 in the prevention and regression of atherosclerotic plaque.• Emerald BioStructures, of Bainbridge Island, Wash., reported a three-year extension of its ongoing collaboration with Brussels, Belgium-based UCB SA, started in 2009, which will provide Emerald with research funding over the three-year period and the opportunity to receive milestones and royalties on future drug product revenues.